In this expert perspective from Hawaiian Eye 2024, Ferhina S. Ali, MD, MPH, discusses expectations for how faricimab will perform in the real world for the treatment of retinal vein occlusion.
The FDA approved Vabysmo (faricimab, Genentech) for the treatment of retinal vein occlusion in 2023.
“I’m excited to see in the real world whether or not we can appreciate some differences in the dual mechanism of faricimab, which has both the anti-VEGF as well as the anti-Ang-2, and if we see differences in how the patients respond to faricimab as compared to anti-VEGF alone,” Ali said.